BACKGROUND: The optimal community-level approach to control pandemic influenza is unknown. METHODS: We estimated the health outcomes and costs of combinations of 4 social distancing strategies and 2 antiviral medication strategies to mitigate an influenza pandemic for a demographically typical US community. We used a social network, agent-based model to estimate strategy effectiveness and an economic model to estimate health resource use and costs. We used data from the literature to estimate clinical outcomes and health care utilization. RESULTS: At 1% influenza mortality, moderate infectivity (R(o) of 2.1 or greater), and 60% population compliance, the preferred strategy is adult and child social distancing, school closure, and antiviral treatment and prophylaxis. This strategy reduces the prevalence of cases in the population from 35% to 10%, averts 2480 cases per 10,000 population, costs $2700 per case averted, and costs $31,300 per quality-adjusted life-year gained, compared with the same strategy without school closure. The addition of school closure to adult and child social distancing and antiviral treatment and prophylaxis, if available, is not cost-effective for viral strains with low infectivity (R(o) of 1.6 and below) and low case fatality rates (below 1%). High population compliance lowers costs to society substantially when the pandemic strain is severe (R(o) of 2.1 or greater). CONCLUSIONS: Multilayered mitigation strategies that include adult and child social distancing, use of antivirals, and school closure are cost-effective for a moderate to severe pandemic. Choice of strategy should be driven by the severity of the pandemic, as defined by the case fatality rate and infectivity.
BACKGROUND: The optimal community-level approach to control pandemic influenza is unknown. METHODS: We estimated the health outcomes and costs of combinations of 4 social distancing strategies and 2 antiviral medication strategies to mitigate an influenza pandemic for a demographically typical US community. We used a social network, agent-based model to estimate strategy effectiveness and an economic model to estimate health resource use and costs. We used data from the literature to estimate clinical outcomes and health care utilization. RESULTS: At 1% influenza mortality, moderate infectivity (R(o) of 2.1 or greater), and 60% population compliance, the preferred strategy is adult and child social distancing, school closure, and antiviral treatment and prophylaxis. This strategy reduces the prevalence of cases in the population from 35% to 10%, averts 2480 cases per 10,000 population, costs $2700 per case averted, and costs $31,300 per quality-adjusted life-year gained, compared with the same strategy without school closure. The addition of school closure to adult and child social distancing and antiviral treatment and prophylaxis, if available, is not cost-effective for viral strains with low infectivity (R(o) of 1.6 and below) and low case fatality rates (below 1%). High population compliance lowers costs to society substantially when the pandemic strain is severe (R(o) of 2.1 or greater). CONCLUSIONS: Multilayered mitigation strategies that include adult and child social distancing, use of antivirals, and school closure are cost-effective for a moderate to severe pandemic. Choice of strategy should be driven by the severity of the pandemic, as defined by the case fatality rate and infectivity.
Authors: Bruce Y Lee; Sarah M Bartsch; Shawn T Brown; Philip Cooley; William D Wheaton; Richard K Zimmerman Journal: Med Care Date: 2015-03 Impact factor: 2.983
Authors: Bruce Y Lee; Sarah M Bartsch; Mercy Mvundura; Courtney Jarrahian; Kristina M Zapf; Kathleen Marinan; Angela R Wateska; Bill Snyder; Savitha Swaminathan; Erica Jacoby; James J Norman; Mark R Prausnitz; Darin Zehrung Journal: Vaccine Date: 2015-03-13 Impact factor: 3.641
Authors: Zaid Haddadin; Jennifer E Schuster; Andrew J Spieker; Herdi Rahman; Anna Blozinski; Laura Stewart; Angela P Campbell; Joana Y Lively; Marian G Michaels; John V Williams; Julie A Boom; Leila C Sahni; Mary Staat; Monica McNeal; Rangaraj Selvarangan; Christopher J Harrison; Geoffrey A Weinberg; Peter G Szilagyi; Janet A Englund; Eileen J Klein; Aaron T Curns; Brian Rha; Gayle E Langley; Aron J Hall; Manish M Patel; Natasha B Halasa Journal: Pediatrics Date: 2021-05-13 Impact factor: 7.124
Authors: Ozgur M Araz; Paul Damien; David A Paltiel; Sean Burke; Bryce van de Geijn; Alison Galvani; Lauren Ancel Meyers Journal: BMC Public Health Date: 2012-06-18 Impact factor: 3.295
Authors: Janetta E Skarp; Laura E Downey; Julius W E Ohrnberger; Lucia Cilloni; Alexandra B Hogan; Abagael L Sykes; Susannah S Wang; Hiral Anil Shah; Mimi Xiao; Katharina Hauck Journal: Appl Health Econ Health Policy Date: 2021-06-11 Impact factor: 3.686